Infant Bacterial Therapeutics is listed on Nasdaq First North and publishes company description
March 21, 2016
Infant Bacterial Therapeutics AB (publ) (“IBT”) has been approved for listing and the company’s series B shares will be traded on Nasdaq First North as from 29 March 2016 with Erik Penser Bankaktiebolag as Certified Adviser. The listing is part of the distribution of all of BioGaia AB’s (publ) shares in IBT to BioGaia’s shareholders, which was resolved at the extraordinary general meeting of BioGaia on 18 March 2016.
A company description has been prepared in connection with the listing and is available on IBT’s website, www.ibtherapeutics.com
For additional information please contact
Staffan Strömberg, CEO, phone: +46 8 410 145 55
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 8 410 145 55
See Press Release in both Swedish and English: